Srinivasan Chinnapaiyan, Ph.D.

Srinivasan Chinnapaiyan, Ph.D.

Assistant Professor

Immunology and Nano-Medicine

Office: AHC1 417B

Phone: 305-348-9173


Curriculum Vitae

Srinivasan Chinnapaiyan, Ph.D., conducts research and mentors students in research activities.

Chinnapaiyan is a member of the Society for Reproductive Biology and Comparative Endocrinology, the Society for Personalized Nano-Medicine, and the American Thoracic Society.

He has published several research papers in peer-reviewed scientific journals and has presented his work both nationally and internationally.


Ph.D., Biochemistry-Endocrinology (Interdisciplinary), Dr. A.L.M. Post Graduate Institute of Basic Medical Sciences, University of Madras, India
MPhil, Endocrinology, Dr. A.L.M. Post Graduate Institute of Basic Medical Sciences, University of Madras, India
M.S., Biochemistry, Annamalai University, India
B.Sc., Biochemistry, University of Madras, India


  • Junior Research Fellowship in Department of Science and Technology (DST), India
  • Senior Research Fellowship in Department of Science and Technology (DST), India
  • Edu-GLIA award, an Initial Training Network funded by European Commission under the Seventh Framework Programme, France

Area of Interest/Specialization

His current research predominantly focuses on mucociliary dysfunction in HIV, smoked substance abuse, and the pathophysiological mechanisms that lead to MCC suppression in people with HIV who also smoke tobacco or abuse illicit drugs. β2-agonists mediated MCC is attenuated in chronic airway diseases (COPD /asthma) and smokers, due to TGF-β mediated suppression of CFTR biogenesis and function. Nevertheless, inhibiting TGF-β signaling can restore CFTR function. Novel therapeutic approaches of CRISPR gene specific microRNA antagonism in HIV and cigarette smoke enhanced COPD patients.

Recent Publications

  1. Chinnapaiyan S, Santiago MJ, Panda K, Rahman MS, Alluin J, Rossi J, et al. A conditional RNA Pol II mono-promoter drives HIV-inducible, CRISPR-mediated cyclin T1 suppression and HIV inhibition. Molecular therapy Nucleic acids. 2023; 32:553-65. doi: 10.1016/j.omtn.2023.04.011. PubMed PMID: 37215150.
  2. Panda K, Chinnapaiyan S, Rahman MS, Santiago MJ, Black SM, Unwalla HJ (2023). Circadian-Coupled Genes Expression and Regulation in HIV-Associated Chronic Obstructive Pulmonary Disease (COPD) and Lung Comorbidities. International Journal of Molecular Sciences . 2023; 24(11):9140. .
  3. Dutta RK, Chinnapaiyan S, Santiago MJ, Rahman I, Unwalla HJ. Gene-specific MicroRNA antagonism protects against HIV Tat and TGF-beta-mediated suppression of CFTR mRNA and function. Biomed Pharmacother. 2021; 142:112090. Epub 2021/09/01. doi: 10.1016/j.biopha.2021.112090. PubMed PMID: 34463266.
  4. Chinnapaiyan S, Dutta RK, Devadoss D, Chand HS, Rahman I, Unwalla HJ (2020). Role of Non-Coding RNAs in Lung Circadian Clock Related Diseases. International journal of molecular sciences , 21(8). doi: 10.3390/ijms21083013.
  5. Chinnapaiyan S Dutta RKNair MChand HSRahman IUnwalla HJ (2019). TGF-β1 increases viral burden and promotes HIV-1 latency in primary differentiated human bronchial epithelial cells . Scientific Reports, 9(1):12552. doi: 10.1038/s41598-019-49056-6.
  6. Dutta RK, Chinnapaiyan S, Rasmussen L, Raju SV, Unwalla HJ (2019). A Neutralizing Aptamer to TGFBR2 and miR-145 Antagonism Rescue Cigarette Smoke- and TGF-β-Mediated CFTR Expression. Molecular Therapy, 27(2):442-455. doi:10.1016/j.ymthe.2018.11.017. Epub 2018 Dec 6.


Active Grants

Agency: NIH/NIDA (A-START): Restoring mucociliary clearance apparatus to mitigate lung inflammation in the context of HIV and cigarette smoke.   
Role: Principal Investigator
Project Period: 08/01/2022 – 07/31/2024